This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate
by Zacks Equity Research
Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones.
Here's Why Amgen Stock is Outperforming Its Industry Of Late
by Zacks Equity Research
Favorable patent ruling related to Enbrel and strong second-quarter results drive Amgen (AMGN) stock 22.6% higher in the past three months.
Amgen Wins Enbrel U.S. Patent Litigation Against Novartis
by Zacks Equity Research
Despite lower demand hurting volumes of Enbrel, it remains the largest drug for Amgen (AMGN). A district court decision prevents Novartis from launching Erelzi, its biosimilar version of Enbrel.
Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Intrexon (XON) posts a narrower-than-expected loss and misses sales estimates in the second quarter of 2019.
Tilray (TLRY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports second-quarter 2019 results.
Has Novartis (NVS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (NVS) Outperforming Other Medical Stocks This Year?
NVS vs. NVO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVS vs. NVO: Which Stock Is the Better Value Option?
2 Marijuana Stocks to Buy Heading into Q2 Earnings and Beyond
by Mitchell Moore
The marijuana industry is projected to grow at an annual rate of about 17% until it reaches $55.8 billion a year in 2025. The cannabis market has roughly tracked the S&P 500' s expansion in 2019 so far.
Mallinckrodt (MNK) Q2 Earnings Beat, Generics Spin-off on Hold
by Zacks Equity Research
Mallinckrodt (MNK) beats on earnings in Q2 but marginally misses on revenues. The company suspends plan to spin-off the generic business for now.
Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies
by Zacks Equity Research
Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.
Aduro (ADRO) Earnings Miss in Q2, Revenues Meet Estimates
by Zacks Equity Research
Aduro (ADRO) suffers wider-than-expected loss in the second quarter while revenues match estimates.
Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger
by Kinjel Shah
AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Lilly (LLY) report Q2 results. Pfizer announces plan to merge off-patent unit, Upjohn with Mylan to form new company.
United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Down Y/Y
by Zacks Equity Research
United Therapeutics (UTHR) beats estimates on both fronts in the second quarter. Loss of exclusivity for Adcirca and lower sales of Remodulin hurts sales.
Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
Ligand (LGND) reports better-than-expected second-quarter 2019 results and maintains view for the full year.
Gilead (GILD) Q2 Earnings & Sales Beat, Sales Guidance Raised
by Zacks Equity Research
Gilead (GILD) beats on Q2 earnings and sales on solid performance of the HIV franchise. The company also raises its sales guidance for the year.
Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Incyte (INCY) reports better-than-expected results for the second quarter of 2019, owing to strong Jakafi sales.
Lilly (LLY) Q2 Earnings Beat, New Drugs Drive Sales, Stock Up
by Zacks Equity Research
Eli Lilly's (LLY) Q2 earnings beat estimates while sales miss. New drugs drive sales despite generic competition to key drug Cialis.
Dr. Reddy's (RDY) Q1 Earnings and Revenues Increase Y/Y
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and sales increase year over year in the first quarter of fiscal 2020.
Are Investors Undervaluing Novartis (NVS) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bayer (BAYRY) Q2 Earnings Match Estimates, Sales Up Y/Y
by Zacks Equity Research
Bayer (BAYRY) reports in-line earnings in the second quarter of 2019.
Will Strong Jakafi Sales Drive Incyte (INCY) Q2 Earnings?
by Zacks Equity Research
Investors will primarily focus on Jakafi sales and pipeline updates, when Incyte (INCY) reports second-quarter 2019 results.
The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies and Novartis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies and Novartis
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.
Top Research Reports for Abbott, Netflix & Philip Morris
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Abbott (ABT), Netflix (NFLX) and Philip Morris (PM).
Is a Beat in Store for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Vaccines segment is likely to witness sales growth in the second quarter.